

FOI 2976

19th March 2025**FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST**

Question 1:

I am analysing the usage of new biologic and targeted medications within dermatology and respiratory medicine. Could you please answer the following questions:

How many patients were treated in February 2025 (or latest available month) by the Dermatology department with the following drugs:

- Abrocitinib (Cibinqo)
- Baricitinib (Olmiant)
- Dupilumab (Dupixent)
- Lebrikizumab (Ebglyss)
- Omalizumab (Xolair)
- Tralokinumab (Adtralza)
- Upadacitinib (Rinvoq)
- Nemolizumab (Nemluvio)

Response:

- Abrocitinib (Cibinqo) - 1
- Baricitinib (Olmiant) - 1
- Dupilumab (Dupixent) - 126
- Lebrikizumab (Ebglyss) - 4
- Omalizumab (Xolair) - 44
- Tralokinumab (Adtralza) - 1
- Upadacitinib (Rinvoq) - 33
- Nemolizumab (Nemluvio) – 0

Question 2:

How many patients were treated in February 2025 (or latest available month) by the Respiratory Medicine departments with the following drugs:

- Benralizumab (Fasenra)
- Dupilumab (Dupixent)
- Mepolizumab (Nucala)
- Omalizumab (Xolair)

- **Reslizumab (Cinqaero)**
- **Tezepelumab (Tezspire)**

Response:

No patients within Respiratory were treated with the medications listed above in February 2025. This is a tertiary level service and all patients deemed potentially appropriate are referred to BHSCCT for consideration.

Email: FOI.team@southerntrust.hscni.net